Bausch Health [BHC] vs Regencell Bioscience [RGC] Detailed Stock Comparison

Bausch Health

NYSE
Loading...

Regencell Bioscience

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Bausch Health wins in 10 metrics, Regencell Bioscience wins in 4 metrics, with 0 ties. Bausch Health appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricBausch HealthRegencell BioscienceBetter
P/E Ratio (TTM)25.69-1,992.17Regencell Bioscience
Price-to-Book Ratio16.851,227.86Bausch Health
Debt-to-Equity Ratio14,787.760.00Regencell Bioscience
PEG Ratio0.02N/AN/A
EV/EBITDA7.52-2,117.91Regencell Bioscience
Profit Margin (TTM)0.99%0.00%Bausch Health
Operating Margin (TTM)18.02%0.00%Bausch Health
EBITDA Margin (TTM)18.02%N/AN/A
Return on Equity14.29%-47.77%Bausch Health
Return on Assets (TTM)4.35%-30.65%Bausch Health
Free Cash Flow (TTM)$1.26B$-4.01MBausch Health
1-Year Return-18.62%10,681.25%Regencell Bioscience
Price-to-Sales Ratio (TTM)0.25N/AN/A
Enterprise Value$23.39B$8.45BBausch Health
EV/Revenue Ratio2.37N/AN/A
Gross Profit Margin (TTM)69.80%N/AN/A
Revenue per Share (TTM)$27$0Bausch Health
Earnings per Share (Diluted)$0.26$-0.01Bausch Health
Beta (Stock Volatility)0.432.05Bausch Health
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Bausch Health vs Regencell Bioscience Stock Performance Analysis

Loading Price Chart...

Bausch Health
Regencell Bioscience
Bausch Health Stock Overview | Regencell Bioscience Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bausch Health-3.14%0.00%-11.73%-5.82%23.00%-18.51%
Regencell Bioscience0.88%5.25%28.44%-6.40%2,169.74%13,169.23%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bausch Health-18.62%0.31%-62.19%-96.36%-75.78%-71.65%
Regencell Bioscience10,681.25%2,169.74%6,060.71%6,060.71%6,060.71%6,060.71%

News Based Sentiment: Bausch Health vs Regencell Bioscience

Bausch Health

News based Sentiment: MIXED

October saw a blend of positive signals – strong insider buying and market gains – alongside cautious analyst commentary and stock price fluctuations. The upcoming Q3 earnings release on October 29th is a key catalyst that will likely shape the investment narrative going forward, making this a moderately important month for investors.

View Bausch Health News Sentiment Analysis

Regencell Bioscience

News based Sentiment: MIXED

October brought a complex mix of news for Regencell, with promising clinical trial results countered by ongoing financial losses and a highly inflated valuation. The index inclusion and insider buying offer some positive signals, but the overall picture remains one of high risk and uncertainty, making it a significant month for investors to reassess their positions.

View Regencell Bioscience News Sentiment Analysis

Performance & Financial Health Analysis: Bausch Health vs Regencell Bioscience

MetricBHCRGC
Market Information
Market Cap i$2.48B$8.46B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,482,270159,099
90 Day Avg. Volume i1,923,373251,796
Last Close$6.47$17.25
52 Week Range$4.25 - $9.85$0.09 - $83.60
% from 52W High-34.31%-79.37%
All-Time High$263.81 (Aug 03, 2015)$950.00 (May 30, 2025)
% from All-Time High-97.55%-98.18%
Growth Metrics
Quarterly Revenue Growth0.05%N/A
Quarterly Earnings Growth13.80%N/A
Financial Health
Profit Margin (TTM) i0.01%0.00%
Operating Margin (TTM) i0.18%0.00%
Return on Equity (TTM) i0.14%-0.48%
Debt to Equity (MRQ) i14,787.760.00
Cash & Liquidity
Book Value per Share (MRQ)$-2.07$0.01
Cash per Share (MRQ)$4.67N/A
Operating Cash Flow (TTM) i$1.51B$-3,881,392
Levered Free Cash Flow (TTM) i$1.35B$-4,301,837
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i$0.00N/A

Valuation & Enterprise Metrics Analysis: Bausch Health vs Regencell Bioscience

MetricBHCRGC
Price Ratios
P/E Ratio (TTM) i25.69-1,992.17
Forward P/E i1.51N/A
PEG Ratio i0.02N/A
Price to Sales (TTM) i0.25N/A
Price to Book (MRQ) i16.851,227.86
Market Capitalization
Market Capitalization i$2.48B$8.46B
Enterprise Value i$23.39B$8.45B
Enterprise Value Metrics
Enterprise to Revenue i2.37N/A
Enterprise to EBITDA i7.52-2,117.91
Risk & Other Metrics
Beta i0.432.05
Book Value per Share (MRQ) i$-2.07$0.01

Financial Statements Comparison: Bausch Health vs Regencell Bioscience

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BHCRGC
Revenue/Sales i$2.53BN/A
Cost of Goods Sold i$764.00MN/A
Gross Profit i$1.77BN/A
Research & Development i$159.00MN/A
Operating Income (EBIT) i$457.00MN/A
EBITDA i$776.00MN/A
Pre-Tax Income i$140.00MN/A
Income Tax i$12.00MN/A
Net Income (Profit) i$128.00MN/A

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BHCRGC
Cash & Equivalents i$1.13B$2.96M
Total Current Assets i$5.73B$8.11M
Total Current Liabilities i$4.26B$193,578
Long-Term Debt i$21.23B$25,934
Total Shareholders Equity i$-240.00M$8.22M
Retained Earnings i$-9.88B$-21.62M
Property, Plant & Equipment iN/A$84,780

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BHCRGC
Operating Cash Flow i$236.00MN/A
Capital Expenditures i$-115.00MN/A
Free Cash Flow i$87.00MN/A
Debt Repayment i$-168.00MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBHCRGC
Shares Short i7.93M1.68M
Short Ratio i3.196.07
Short % of Float i0.02%0.02%
Average Daily Volume (10 Day) i1,482,270159,099
Average Daily Volume (90 Day) i1,923,373251,796
Shares Outstanding i367.84M494.49M
Float Shares i225.63M18.43M
% Held by Insiders i0.11%0.96%
% Held by Institutions i0.68%0.00%

Dividend Analysis & Yield Comparison: Bausch Health vs Regencell Bioscience

MetricBHCRGC
Last 12-Month Dividend i$0.00N/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i$0.00N/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends i$0.00N/A
Ex-Dividend DateN/AN/A